April 2021

Editor’s note: The ALS News Today team is providing in-depth coverage of the 2021 MDA Virtual Clinical and Scientific Conference, March 15–18. Go here to read the latest stories from the conference.   WVE-004, an investigational treatment for people with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) who carry C9orf72 gene mutations, lowered the […]

Under an agreement with the University of Kansas, PharmaTher has gained exclusive worldwide rights to develop and possibly commercialize ketamine as a therapy for amyotrophic lateral sclerosis (ALS). “We are pleased to have added the [ALS] program to our already impressive development pipeline that focuses on novel uses, formulations and delivery of ketamine in the